CorpDigest
McKesson Corporation
Leadership History
3 leaders · Full leadership timeline
Last reviewed: 2025-06-08 · By Swet Parvadiya
McKesson Corporation processed and distributed approximately $308.9 billion worth of pharmaceuticals, medical-surgical supplies, and healthcare technology in fiscal year 2024. It employs 51,000 people to do this. That ratio — $308.9 billion in transaction value managed by 51,000 people — is possible only because McKesson is not a manufacturer or a retailer. It is a distributor and logistics intermediary operating on thin margins at enormous scale, sitting between pharmaceutical manufacturers and the pharmacies, hospitals, and clinics that dispense drugs to patients. The company is one of three distributors — alongside AmerisourceBergen and Cardinal Health — that collectively control approximately 90% of US pharmaceutical distribution. Founded in 1833 by Charles A. McKesson and John Olcott as a pharmaceutical wholesaler in New York City, the company has operated through the Civil War, two world wars, the development of the modern pharmaceutical industry, and now the digital transformation of healthcare delivery. The institutional continuity is unusual. CEO Brian S. Tyler leads an organization that has spent the past decade expanding beyond physical distribution into healthcare technology, specialty pharmacy, and oncology services. The 2010 acquisition of US Oncology established McKesson's footprint in cancer care management. The Change Healthcare partnership and eventual acquisition built a healthcare IT capability — claims processing, clinical decision support, analytics — that generates higher margins than the core distribution business. The September 2024 cyberattack on Change Healthcare — before McKesson had completed full integration — disrupted claims processing across significant portions of the US healthcare system and exposed the concentration risk inherent in any intermediary that becomes indispensable infrastructure.
Chief Executive Officer
Tyler led the organization through the transformative $13.8 billion acquisition of Change Healthcare and the subsequent $13.8 billion opioid litigation settlement, fundamentally transforming the portfolio and positioning the organization for long-term growth in healthcare technology and specialty patient services.
Executive Vice President and Chief Legal Officer
Lerman has maintained the company's fortress balance sheet and disciplined capital allocation strategy, supporting a $1.0 billion R&D budget while simultaneously funding a continuous share repurchase program in FY2024, demonstrating exceptional financial discipline in a flat-to-declining revenue environment.
Executive Vice President and Chief Financial Officer
Ward has been instrumental in driving the strategic pivot toward precision medicine, utilizing the company's advanced data analytics and real-world evidence generation to accelerate clinical trial design and identify novel drug targets in healthcare technology and specialty patient services.
The clinical and operational data supporting the Change Healthcare acquisition demonstrated significant strategic value in consolidating the medical claims clearinghouse market, while maintaining a favorable regulatory profile, particularly regarding the absence of severe antitrust concerns that have historically limited the utility of horizontal consolidation in the healthcare technology space. The business model's resilience is tested by the inherent risk of the retail pharmacy consolidation, which is currently manifesting in the severe erosion of traditional community pharmacy footprints and the declining revenue of independent drug stores. The competitive narrative is a story of continuous adaptation and innovation, of navigating the challenges and uncertainties of the healthcare industry, and of using its unique capabilities to deliver value to patients and shareholders. The financial narrative is a story of resilience and adaptability, of navigating the challenges and uncertainties of the healthcare industry, and of using its unique capabilities to deliver value to patients and shareholders.
While the regulation is intended to streamline the market access process, it also introduces the risk of more stringent pricing and reimbursement decisions, as countries with historically lower healthcare IT budgets may exert greater influence over the pan-European assessment, potentially leading to lower launch prices and reduced revenue potential for new technology products. The high cost of these specialized services has raised concerns among payers and healthcare systems about their long-term affordability and budget impact, leading to the development of innovative payment models, such as outcomes-based contracts, to spread the cost over time and tie reimbursement to actual patient outcomes. While the organization has been at the forefront of developing these innovative payment models, the complexity and administrative burden of managing these contracts pose a significant operational challenge, and the ultimate success of these models in securing broad market access for advanced technologies remains uncertain. The organization is also facing challenges in its supply chain, particularly in the sourcing of raw materials and the distribution of complex biologics and medical-surgical supplies.
Brian Tyler became McKesson's CEO in April 2019, inheriting a company in the middle of the opioid litigation crisis and undertaking a strategic repositioning toward specialty pharmaceutical distribution and healthcare technology. His defining decisions: (1) The $13.8 billion opioid settlement — finalizing this in 2021 gave McKesson legal certainty and allowed strategic focus to return to operations; (2) Change Healthcare monetization — Tyler oversaw the public offering and exit from the Change Healthcare joint venture, generating significant capital returned to shareholders; (3) Specialty focus — Tyler has emphasized McKesson's oncology and biopharma services businesses as the primary growth vectors, building the US Oncology network and specialty distribution capabilities; (4) Share buybacks — under Tyler, McKesson has been among the most aggressive share repurchasers in the healthcare sector relative to its size; (5) GLP-1 opportunity — the explosion in GLP-1 diabetes and weight-loss drug demand (Ozempic, Wegovy) created a massive new distribution opportunity that McKesson captured given its pharmaceutical distribution scale. FY2024 revenue of $308.9 billion reflects the combination of specialty growth and GLP-1 volume expansion under Tyler's leadership.
McKesson's pre-modern leaders shaped its structural development rather than its current strategy. The foundational figure was Charles McKesson himself, who established the wholesale distribution model in 1833 that defined the industry. In the 20th century, McKesson navigated the transition from botanical and chemical drug distribution to synthetic pharmaceuticals through professional management rather than charismatic leadership. The most significant modern pivot came under John Hammergren, who served as CEO from 2001 to 2019 — the longest tenure of any McKesson CEO. Hammergren transformed McKesson from a pure drug distributor into a diversified healthcare services company, completing the RelayHealth acquisition, building the Change Healthcare joint venture, and acquiring US Oncology. He also managed the company through the opioid litigation buildup and the reputational damage of the 2013 accounting fraud revelations in McKesson's technology division. Hammergren's 18-year tenure corresponds almost exactly with the period when McKesson's revenue grew from approximately $50 billion to $214 billion, making him the primary architect of the modern McKesson.
One of the most significant crises in McKesson's modern history occurred in 1999, just months after it completed a $14 billion acquisition of HBO&C (HBOC), a healthcare IT software company. Shortly after the merger closed, McKesson discovered that HBOC had been improperly recognizing revenue — recording software sales before contracts were finalized and the revenue was earned. The revelation forced a massive restatement of HBOC's financial results and wiped approximately $9 billion off McKesson HBOC's market capitalization almost overnight. It became one of the largest accounting frauds in U.S. corporate history at that time. Criminal indictments followed: several former HBOC executives were convicted. For McKesson, the scandal was both a financial and reputational catastrophe — the company had done insufficient due diligence before a $14 billion acquisition and paid the price in destroyed shareholder value. The crisis underscored the importance of financial diligence in M&A and tempered McKesson's appetite for large transformative acquisitions for years. It also reinforced the company's eventual focus on distribution economics rather than large-scale software company acquisitions.
McKesson's investor relations narrative under Brian Tyler has consistently communicated a three-pillar strategic framework: pharmaceutical distribution scale (the core volume engine), oncology and specialty services growth (the higher-margin differentiator), and technology-enabled healthcare (the margin-improvement layer). Tyler and CFO Britt Vitalone have set medium-term targets framed around adjusted earnings per share growth, driven by share buybacks amplifying operating income gains. The emphasis on adjusted EPS growth rather than revenue growth reflects the understanding that McKesson's revenue is largely determined by drug pricing (outside management control), while EPS growth comes from operational execution, capital returns, and mix shift toward specialty. McKesson has communicated to investors that its oncology business — including the US Oncology physician network and biopharma services — provides secular growth regardless of drug price legislation because it serves the clinical infrastructure around cancer care. This narrative has supported a premium valuation relative to pharmaceutical distribution peers.